MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

DEVICE5 trials

Sponsors

MediBeacon, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Chronic Kidney DiseaseGlomerular Filtration RateHeart FailureKidney DiseasesKidney FailureKidney Injury

Phase 3

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

CompletedNCT05425719

MediBeaconChronic Kidney Disease

Start: 2022-06-14End: 2023-02-15Updated: 2024-04-18

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

CompletedNCT05777174

MediBeaconKidney Diseases, Kidney Failure, Kidney Injury

Start: 2023-03-20End: 2024-04-15Updated: 2025-03-28

A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants

CompletedNCT05943977

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Kidney Diseases, Kidney Failure, Kidney Injury

Start: 2023-03-02End: 2023-11-30Updated: 2024-01-02

Unknown Phase

Evaluation of Protein Loading on Measurement of Renal Reserve

Not yet recruitingNCT07335614

MediBeaconGlomerular Filtration Rate

Start: 2026-09-01End: 2027-01-01Target: 25Updated: 2026-08-14

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

RecruitingNCT07349797

MediBeaconGlomerular Filtration Rate, Heart Failure

Start: 2026-08-10End: 2027-01-01Target: 15Updated: 2026-08-14